General Notes
This product (Catalog No. DMAB-CBAS072) is a mouse-derived monoclonal antibody raised against human KRT19. It has been affinity purified by Protein A. KRT19 (Keratin 19) is a type I cytokeratin protein that plays a crucial role in various cancers. It is highly expressed in many epithelial tumors like ovarian, breast, and lung cancers, and is associated with cancer progression, metastasis, and poor prognosis.KRT19 regulates cancer stem cell properties, proliferation, invasion, and chemotherapy resistance, though its exact mechanisms seem to be context-dependent. In ovarian cancer, KRT19 is a promising prognostic biomarker that correlates with tumor immune infiltration and expression of immunomodulators. In breast cancer, KRT19 interacts with the β-catenin/RAC1 complex to promote epithelial-mesenchymal transition and metastasis.However, its role can be contradictory in some breast cancer subtypes. In lung cancer, high KRT19 expression is an independent prognostic factor for poor survival, especially in squamous cell carcinoma.
DMAB-CBAS072 is suitable for use in ELISA(Cap) application.
DMAB-CBAS072 is supplied as a liquid formulation in Phosphate-buffered saline (PBS), carrier-free, with optional 0.09% sodium azide. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
COA
Publication 
Loading ......
